Recruiting
Phase 2

Atropine Eye Drops

Sponsor:

Rehan Ahmed

Code:

NCT07676981

Conditions

Epiphora

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atropine ophthalmic solution

Study Details

Brief summary:

The goal of this clinical trial is to learn if low-dose atropine eye drops work to reduce excessive watery eyes (epiphora) in adults. It will also learn about the safety of the eye drops.

The main questions it aims to answer are:

Do the eye drops reduce how often participants have watery eyes? What medical problems do participants have when taking the eye drops?

Researchers will compare two strengths of the eye drops (0.005% and 0.01%) to see whether one works better than the other and whether the lower strength works as well as the higher one.

Participants will:

  • Use the assigned eye drops in the affected eye(s) for one week
  • Visit the clinic twice for checkups and eye tests
  • Receive a follow-up phone call about two weeks after starting, to check on any symptoms

Conditions

Epiphora

Study ID

NCT07676981

Start date

Jun, 2026

Status verified date

Jun, 2026

Completion date

Jul, 2026

Anticipated

Primary completion date

Jul, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

You may be able to join if you:

  • Are 18 years or older
  • Have vision of 20/200 or better in at least one eye
  • Have watery eyes (epiphora) bad enough to need wiping or dabbing at least twice a day
  • Have watering caused by a functional/idiopathic, gustatory ("crocodile tears"), environmentally triggered (reflex), or obstructive cause - in one or both eyes
  • Have a healthy eye surface, with no significant dry eye, active eye infection, or active eye inflammation
  • Have adequate eyelid position and tone, where surgery is not the main treatment needed and reducing tear production is likely to help
  • Are willing and able to put drops in your eye(s) once each night for 7 days and attend the study visits
  • Can understand and follow the study procedures and communicate with study staff (an interpreter is allowed)

You will not be able to join if you:

  • Have significant dry eye disease
  • Have had an active eye infection within the past 30 days
  • Have an active tear-sac infection, or a blocked tear duct that needs urgent surgery (a blocked tear duct that does not need surgery is allowed)
  • Currently use eye drops that affect tear production or eye-surface testing, unless you are willing to stop them for the study
  • Are allergic to, or should not take, atropine, similar (anticholinergic) medicines, or any ingredient in the study drops
  • Have narrow-angle or angle-closure glaucoma, where dilating the pupil would not be safe for you
  • Are pregnant or breastfeeding
  • Are taking part in another interventional study, or took part in one within 30 days before screening
  • Have any condition that, in the doctor's judgment, would make it unsafe for you to join or hard to follow the study

Study Design

Enrollment

18 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Atropine ophthalmic solution 0.005%

Atropine ophthalmic solution 0.005%

experimental: Atropine ophthalmic solution 0.01%

Atropine ophthalmic solution 0.01%

Interventions

Atropine ophthalmic solution

The interventions are two low doses of atropine ophthalmic solution

Primary outcome measure

  • Munk Score Change [ Time Frame: Time Frame: From enrollment to the end of treatment at 1 week ]

Central Contacts and Locations

Central contacts

Rehan Ahmed

713-661-6500studytearing@gmail.com

Locations

Greater Houston Eye Consultants

Recruiting

Houston, Texas, United States, 77098

Contacts

Rehan Ahmed, MD

7136616500studytearing@gmail.com

North Texas Eye Specialists

Recruiting

Mesquite, Texas, United States, 75150

Contacts

Rehan Ahmed, MD

972-807-5744studytearing@gmail.com

More Information

Sponsor

Rehan Ahmed

Last update posted

Jun 30, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Rehan Ahmed on 2026-06-30.